Polychlorinated biphenyls — PCBs — were among the most widely used industrial chemicals of the 20th century, valued for their stability and insulating properties in electrical equipment. Monsanto Company held a monopoly on U.S. production from 1935 until the federal ban in 1976. Internal company documents obtained through litigation reveal that Monsanto's own scientists documented severe toxicity in laboratory animals and workers by the mid-1960s. Rather than halt production or warn customers and communities, the company chose to continue manufacturing PCBs while actively suppressing unfavorable research, fighting regulatory efforts, and concealing health data from regulators and the public. The contamination persists globally today.
Polychlorinated biphenyls — PCBs — entered commercial production in the United States in 1929, manufactured exclusively by the Swann Chemical Company in Anniston, Alabama. In 1935, Monsanto Company acquired Swann and inherited complete control of the American PCB market, a monopoly it would maintain for the next 42 years. Marketed under the trade name Aroclor, PCBs were valued for properties that made them nearly ideal for industrial applications: they did not burn, did not conduct electricity, resisted chemical breakdown, and remained stable across extreme temperatures.
These characteristics made PCBs indispensable in the expanding electrical industry. General Electric, Westinghouse, and other manufacturers incorporated Aroclor products into transformers and capacitors that powered the American electrical grid. PCBs were also used in hydraulic fluids, heat transfer systems, carbonless copy paper, plasticizers, and numerous other applications. By the time Congress banned their production in 1976, Monsanto had manufactured an estimated 1.25 billion pounds of PCBs in the United States.
The same stability that made PCBs commercially valuable would prove to be their environmental curse. PCBs do not break down through natural processes. They accumulate in fatty tissue and concentrate up the food chain through a process called biomagnification. A PCB molecule discharged into a river in 1950 remains a PCB molecule today, migrating through sediment, water, and organisms in concentrations that increase at each trophic level.
Monsanto's internal documents, disclosed through decades of litigation, reveal that the company had evidence of PCB toxicity far earlier than public acknowledgment would suggest. A 1937 study by Cecil Drinker at Harvard School of Public Health, commissioned by Monsanto after workers at the Anniston plant developed chloracne and liver damage, found that PCB exposure caused severe systemic toxicity. Drinker reported his findings to Monsanto but the company did not publish the results or share them with regulatory authorities.
By the 1950s, Monsanto scientists had documented additional health effects in exposed workers, including liver dysfunction, skin lesions, and neurological symptoms. Internal correspondence shows company physicians recommended improved ventilation and protective equipment at manufacturing facilities but did not suggest halting production or warning downstream users about potential risks.
The 1960s brought accumulating evidence that could no longer be contained within internal files. In 1966, Swedish chemist Sören Jensen published research detecting PCBs in wildlife, fish, and human tissue samples across Scandinavia. Jensen's findings demonstrated that PCBs had become ubiquitous environmental contaminants despite their supposedly controlled industrial use.
"We can't afford to lose one dollar of business. We have too much at stake."
Internal Monsanto correspondence — Disclosed in litigation, 1970That same year, an internal Monsanto memo acknowledged that PCBs were "exhibiting a greater degree of hazard to human health than we had anticipated." The memo did not recommend halting production. Instead, company officials focused on managing public relations and regulatory responses to limit business disruption.
Nowhere was Monsanto's knowledge of PCB dangers more extensively documented than in Anniston, Alabama, where the company operated its primary PCB manufacturing plant from 1929 to 1971. Internal company records show Monsanto knew it was severely contaminating the surrounding community but chose to continue operations without disclosure.
In 1969, Monsanto scientists conducted tests on fish from Snow Creek, which received wastewater discharge from the Anniston plant. The fish contained PCB concentrations of 7,500 times the Food and Drug Administration's safety limit. Company officials did not share these results with Alabama environmental authorities, the FDA, or Anniston residents. A 1966 internal memo had already noted that PCB discharge into local creeks was causing "considerable fish kills" and that "the problem involves the entire community."
Monsanto also buried PCB-contaminated waste in unlined landfills on the Anniston plant site. PCBs leached into groundwater and spread through the surrounding soil. By the 1990s, when systematic environmental testing finally occurred, residential yards in predominantly Black neighborhoods adjacent to the plant showed soil contamination up to 940 times the EPA's cleanup threshold.
The full extent of Monsanto's knowledge and concealment emerged only through litigation. In 1996, Anniston residents filed the first of what would become a consolidated class action lawsuit. Discovery produced thousands of internal Monsanto documents spanning decades. The paper trail showed systematic suppression of health data, deliberate non-disclosure to regulators, and corporate decision-making that explicitly prioritized profit over public health.
As scientific evidence of PCB toxicity accumulated in the late 1960s and early 1970s, Monsanto fought aggressively against regulation. The company funded its own research designed to demonstrate safety, challenged unfavorable independent studies, and lobbied extensively against restrictions on PCB use.
In 1968, more than 1,800 people in western Japan were poisoned by rice oil contaminated with PCBs and related compounds — an incident known as Yusho disease. Victims developed severe chloracne, liver damage, immune suppression, and neurological problems. Follow-up studies documented elevated cancer rates decades later. The Yusho incident provided the first large-scale human evidence of acute PCB toxicity and galvanized international concern.
The newly created Environmental Protection Agency began investigating PCB contamination in U.S. waterways in 1971. EPA scientists documented widespread presence of PCBs in fish tissue and sediment. The agency proposed restrictions on PCB use, which Monsanto and electrical equipment manufacturers opposed, arguing that suitable replacement fluids did not exist and that existing uses posed minimal risk.
The magnitude of PCB contamination became undeniable as testing expanded. General Electric had discharged an estimated 1.3 million pounds of PCBs into New York's Hudson River from manufacturing plants in Fort Edward and Hudson Falls. The contamination extended 200 miles downriver. Across the Great Lakes, PCB concentrations in fish exceeded safety limits for human consumption. In California's San Francisco Bay, sediment samples showed severe PCB contamination from multiple industrial sources.
By the mid-1970s, scientific consensus on PCB toxicity was overwhelming. Studies had documented carcinogenicity in laboratory animals, reproductive and developmental effects, immune system suppression, and endocrine disruption. Dr. Renate Kimbrough's 1975 study at the Centers for Disease Control demonstrated that PCBs caused liver tumors in rats — findings that would later contribute to their classification as human carcinogens.
In 1976, Congress passed the Toxic Substances Control Act, landmark environmental legislation that gave the EPA authority to regulate chemicals posing unreasonable risks. TSCA specifically singled out PCBs, mandating that production cease and existing uses be phased out. The law required manufacturers to track PCB-containing equipment and established disposal requirements for contaminated materials.
Monsanto ceased PCB production in 1977. The EPA issued comprehensive regulations in 1979 prohibiting manufacture, processing, and distribution of PCBs, with limited exceptions for totally enclosed electrical equipment. After 42 years of monopoly production and despite internal knowledge of severe toxicity for at least a decade, Monsanto's PCB business finally ended — not through voluntary corporate action but through federal mandate.
The end of production did not end the problem. PCBs persist in the environment indefinitely. The EPA estimates that more than 750 million pounds of PCBs remain in use in older transformers, capacitors, fluorescent light ballasts, and other electrical equipment in buildings and infrastructure across the United States. As this equipment ages and fails, PCBs continue to be released.
PCB-contaminated sites across the United States require extensive and expensive remediation. The Hudson River cleanup alone cost General Electric $1.7 billion to dredge 2.75 million cubic yards of contaminated sediment between 2009 and 2015. Similar cleanup projects continue on the Fox River in Wisconsin, the Housatonic River in Massachusetts, and dozens of other locations. The EPA estimates total cleanup costs for PCB-contaminated Superfund sites exceed $10 billion.
The contamination extends globally. PCBs volatilize from contaminated soil and water, traveling through the atmosphere to deposit in environments far from production sites. Researchers have detected PCBs in Arctic ice, Antarctic penguins, deep ocean sediments, and alpine lakes that have never had industrial development. Indigenous communities in the Arctic, whose traditional diet relies on marine mammals, now face some of the highest human PCB exposure levels on Earth.
In February 2002, an Alabama jury in the Abernathy v. Monsanto case found the company liable for negligence, wantonness, suppression of truth, nuisance, trespass, and outrage in its contamination of Anniston. The jury awarded $700 million in punitive damages — later reduced to $300 million on appeal — recognizing the egregious nature of Monsanto's conduct over decades.
"We are particularly concerned about the effect [PCBs] might have on the entire community. The problem involves the entire community."
Internal Monsanto memo — 1966, disclosed in Abernathy litigationMore than 20,000 Anniston residents eventually received settlements. The documents disclosed in this litigation became a roadmap for PCB cases nationwide, revealing the extent of corporate knowledge, deliberate concealment, and regulatory manipulation across decades of production.
The legal principle established in these cases — that manufacturers can be held liable for contamination and health damages even decades after the fact — has implications beyond PCBs. The Anniston documents demonstrated that internal corporate knowledge, deliberately concealed from regulators and the public, could be recovered through discovery and used to pierce defenses of regulatory compliance and state-of-the-art knowledge.
The health effects of PCB exposure are now extensively documented. In 2013, the International Agency for Research on Cancer upgraded PCBs from "probably carcinogenic to humans" (Group 2A) to "carcinogenic to humans" (Group 1) based on sufficient evidence in both human epidemiological studies and animal research. The evaluation cited evidence linking PCB exposure to malignant melanoma and, with varying degrees of certainty, to non-Hodgkin lymphoma and cancers of the breast, liver, and gallbladder.
Beyond cancer, PCBs disrupt endocrine function, interfere with thyroid hormone regulation, suppress immune system function, and cause neurodevelopmental effects. Studies of children exposed to PCBs in utero show reduced IQ scores, attention deficits, and impaired executive function. The effects are permanent and occur at exposure levels far below those that cause acute poisoning.
Occupational studies of workers exposed to PCBs during manufacturing provide the strongest human evidence. These studies consistently show elevated rates of liver disease, diabetes, and certain cancers. The workers at Monsanto's Anniston and Sauget plants, exposed to the highest concentrations, developed elevated mortality rates from liver cancer and other PCB-associated diseases.
The global nature of PCB contamination led to international action. In 2001, more than 90 countries signed the Stockholm Convention on Persistent Organic Pollutants, a treaty designed to eliminate or severely restrict chemicals that persist in the environment, accumulate in living organisms, and pose risks to human health. PCBs were among the original 12 chemicals targeted — the so-called "dirty dozen."
The Stockholm Convention requires parties to eliminate PCB production, phase out PCB use by 2025, and manage PCB wastes in an environmentally sound manner by 2028. As of 2024, 185 countries have ratified the convention. Implementation has been uneven, particularly in developing nations where resources for identifying and removing PCB-containing equipment are limited.
The treaty acknowledges that complete elimination of PCBs from the global environment is impossible given their persistence and the scale of historical production. The goal is containment and gradual reduction through removal of PCB-containing equipment, secure disposal of contaminated materials, and remediation of heavily contaminated sites.
Monsanto's handling of PCB liabilities through corporate restructuring deserves examination. In 1997, Monsanto spun off its chemical operations, including PCB-related liabilities, into a new company called Solutia Inc. The separation allowed Monsanto to focus on its more profitable agricultural biotechnology business while isolating historical chemical contamination liabilities in a separate corporate entity.
Solutia filed for bankruptcy in 2003, citing in part the costs of PCB litigation and environmental remediation. The company emerged from bankruptcy in 2008 with restructured obligations and was acquired by Eastman Chemical Company in 2012 for $4.7 billion. PCB cleanup costs and legal liabilities were allocated among Monsanto, Solutia, and successor companies through bankruptcy proceedings.
Monsanto itself was acquired by Bayer AG in 2018 for $63 billion, primarily for its agricultural products business. Bayer inherited ongoing PCB-related liabilities, though the most significant contamination cases had been resolved or were in advanced litigation by that point. The corporate reorganizations demonstrate how liability for environmental contamination can be managed through legal structures even as cleanup obligations persist for decades.
The Monsanto PCB case illustrates several patterns that recur across environmental health disasters. First, internal corporate knowledge of hazards preceded external disclosure by years or decades. Monsanto had evidence of severe PCB toxicity by the mid-1960s but continued production until legally compelled to stop in 1977.
Second, contamination extended far beyond the point of discharge and persisted far longer than manufacturing operations. PCBs produced in Anniston between 1935 and 1971 remain in the environment today and will continue contaminating ecosystems and human populations for generations.
Third, the costs of cleanup and compensation vastly exceeded any deterrent value. Monsanto paid hundreds of millions in settlements and cleanup costs, but these payments came decades after the damage occurred and after much of the economic benefit of PCB production had been realized.
Fourth, regulation followed rather than preceded industry. The EPA was not created until 1970, after 35 years of PCB production. Comprehensive restrictions did not come until 1976, despite accumulating evidence throughout the 1960s. Corporate resistance to regulation delayed action even as scientific consensus solidified.
The documents disclosed in PCB litigation reveal the architecture of corporate decision-making when profit and public health conflict. Internal correspondence shows explicit awareness of community-wide contamination, calculations about maintaining market share, and strategies for managing regulatory and public relations challenges. The case demonstrates that environmental catastrophes are not accidents or failures of oversight — they are often the predictable result of documented decisions made by named individuals pursuing institutional objectives.
As of 2024, PCB contamination remains a major environmental health concern. Fish consumption advisories remain in effect for portions of the Hudson River, Great Lakes, and dozens of other water bodies. The EPA maintains an active list of PCB-contaminated Superfund sites requiring remediation. Cleanup continues at sites contaminated decades ago, funded by responsible parties or, where those parties no longer exist or lack resources, by taxpayers through Superfund appropriations.
PCB concentrations in human blood and tissue have declined since the production ban but remain detectable in virtually all tested populations. Exposure continues through consumption of contaminated fish, contact with contaminated soil, and proximity to aging PCB-containing electrical equipment and building materials. The National Health and Nutrition Examination Survey (NHANES) conducted by the CDC continues to detect PCBs in serum samples from representative U.S. populations.
The legal and regulatory framework established through the PCB case — particularly the principle that manufacturers can be held liable for historic contamination based on internal knowledge they possessed but concealed — has shaped subsequent environmental litigation on lead paint, asbestos, PFAS chemicals, and other persistent pollutants. The Anniston documents demonstrated that the paper trail of corporate decision-making could be recovered and used to establish liability decades after the fact.
More than 750 million pounds of PCBs remain in use or await disposal in the United States alone. The cleanup costs already incurred represent only a fraction of the total economic burden that PCB contamination will ultimately impose. And the public health costs — cancers, neurodevelopmental impairments, immune dysfunction — are impossible to fully quantify but will persist for generations after the last PCB molecule is finally secured or degraded.